JP2020516594A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516594A5
JP2020516594A5 JP2019554417A JP2019554417A JP2020516594A5 JP 2020516594 A5 JP2020516594 A5 JP 2020516594A5 JP 2019554417 A JP2019554417 A JP 2019554417A JP 2019554417 A JP2019554417 A JP 2019554417A JP 2020516594 A5 JP2020516594 A5 JP 2020516594A5
Authority
JP
Japan
Prior art keywords
composition according
composition
chain
cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516594A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/000510 external-priority patent/WO2018185564A2/en
Publication of JP2020516594A publication Critical patent/JP2020516594A/ja
Publication of JP2020516594A5 publication Critical patent/JP2020516594A5/ja
Priority to JP2024024899A priority Critical patent/JP2024073459A/ja
Pending legal-status Critical Current

Links

JP2019554417A 2017-04-07 2018-04-05 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ Pending JP2020516594A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024024899A JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483298P 2017-04-07 2017-04-07
US62/483,298 2017-04-07
PCT/IB2018/000510 WO2018185564A2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024024899A Division JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Publications (2)

Publication Number Publication Date
JP2020516594A JP2020516594A (ja) 2020-06-11
JP2020516594A5 true JP2020516594A5 (https=) 2021-05-13

Family

ID=63713282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554417A Pending JP2020516594A (ja) 2017-04-07 2018-04-05 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ
JP2024024899A Pending JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024024899A Pending JP2024073459A (ja) 2017-04-07 2024-02-21 ナノメディシンにおける受容体リガンド相互作用の効力を測定するためのアッセイ

Country Status (13)

Country Link
US (2) US20200057048A1 (https=)
EP (1) EP3607058A4 (https=)
JP (2) JP2020516594A (https=)
KR (1) KR20200004807A (https=)
CN (1) CN110945120B (https=)
AU (1) AU2018248961B2 (https=)
BR (1) BR112019021022A2 (https=)
CO (1) CO2019011018A2 (https=)
IL (1) IL269846A (https=)
MX (1) MX2019012058A (https=)
RU (1) RU2019135533A (https=)
SG (1) SG11201909290TA (https=)
WO (1) WO2018185564A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership Methods of treating autoimmune disease
CN112585162B (zh) * 2018-08-06 2025-01-28 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
GB201906127D0 (en) * 2019-05-01 2019-06-12 Immutep S A Assays
EP3958892A4 (en) * 2019-05-23 2023-06-14 UTI Limited Partnership METHOD OF TREATMENT OF LIVER DISEASE
KR20220150276A (ko) * 2020-01-11 2022-11-10 시벡 바이오테크놀로지스, 엘엘씨 진핵생물로의 진핵생물-번역가능한 mRNA의 생산 및 전달을 위한 미생물 시스템
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
WO2021148683A2 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) * 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment
CN113960003B (zh) * 2021-10-20 2023-10-24 吉林大学 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器
US11873507B2 (en) * 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
EP4249062A1 (en) * 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN115125205A (zh) * 2022-06-14 2022-09-30 中国医学科学院生物医学工程研究所 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法
WO2024248042A1 (ja) * 2023-05-29 2024-12-05 国立大学法人 東京大学 ＭｕＳＫを標的とする新規化合物及びその用途
AU2024346292A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU3896699A (en) 1998-05-07 1999-11-23 Regents Of The University Of California, The Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
DE60226852D1 (de) 2001-03-13 2008-07-10 Novartis Ag Lentivirale verpackungskonstrukte
GB0417954D0 (en) * 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
AU2008222678B2 (en) * 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2010055510A2 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA2813064C (en) 2010-09-29 2021-06-01 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US8809057B2 (en) * 2012-01-04 2014-08-19 Raytheon Bbn Technologies Corp. Methods of evaluating gene expression levels
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
JP6014440B2 (ja) 2012-09-26 2016-10-25 日立オートモティブシステムズ株式会社 移動物体認識装置
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
DK3220927T3 (en) * 2014-11-20 2022-02-14 Promega Corp Systems and methods for assessing modulators of immune checkpoints
EP3233903B1 (en) * 2014-12-19 2020-12-09 ETH Zürich Chimeric antigen receptors and methods of use
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
KR20260048600A (ko) * 2015-03-27 2026-04-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 t 세포 및 이의 제조 및 사용 방법
ES3055030T3 (en) * 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
HK1253694A1 (zh) * 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T细胞受体文库
JP2018531593A (ja) * 2015-09-11 2018-11-01 アジェナス インコーポレイテッド 操作された宿主細胞及びそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2020516594A5 (https=)
CN110730821B (zh) 增强的hAT家族转座子介导的基因转移及相关组合物、系统和方法
Park et al. Mitochondrial DNA mutations in disease and aging
JP7733865B2 (ja) 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
AU2017336100B2 (en) Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
ES2821655T5 (es) Vectores de ADN no integrantes para la modificación genética de células
RU2019135533A (ru) Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах
JP2018509151A5 (https=)
JP2017503485A (ja) 遺伝子産物の発現、構造情報、及び誘導性モジュラーｃａｓ酵素を変更するためのｃｒｉｓｐｒ−ｃａｓ系並びに方法
US20170175136A1 (en) Genomic insulator elements and uses thereof
US9127283B2 (en) Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
TWI900630B (zh) 用於富集基因改造t細胞之方法
Anderson et al. Regulation of the expression and activity of Unr in mammalian cells
Jumlongras et al. An evolutionarily conserved enhancer regulates Bmp4 expression in developing incisor and limb bud
US20220017888A1 (en) Method for inducing deletion in genomic dna
Andersen et al. Sperm 1: a POU-domain gene transiently expressed immediately before meiosis I in the male germ cell.
CN104293815A (zh) 一种纳米基因疫苗及其制备方法和应用
Pouilhe et al. Direct regulation of vHnf1 by retinoic acid signaling and MAF-related factors in the neural tube
US20120094375A1 (en) Enhanced engineered native promoters and uses thereof
JP2009240233A5 (https=)
JP2013034401A (ja) アストロサイトで遺伝子を発現させるためのベクター
TW202448922A (zh) 改良之ｅｒｔ２突變體、可誘導型細胞死亡系統及其用途
US20110173707A1 (en) System for the Determination of Molecules Altering the Function of Interferon, Method Therefor and Compounds Altering Interferon Activity
Sinnott et al. Engineering a human-based translational activator for targeted protein expression restoration
Whalen Promoters, enhancers, and inducible elements for gene therapy